<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555919</url>
  </required_header>
  <id_info>
    <org_study_id>91484</org_study_id>
    <secondary_id>2005-005581-36</secondary_id>
    <secondary_id>309821</secondary_id>
    <nct_id>NCT00555919</nct_id>
  </id_info>
  <brief_title>ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer</brief_title>
  <official_title>Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211
      (100 mg vs. 25 mg) as second-line endocrine therapy for postmenopausal women with hormone
      receptor-positive metastatic breast cancer.Once the cancer has spread beyond the lymph nodes
      to areas such as e.g. the skin, soft tissues, lung, and liver it is called metastatic breast
      cancer. Patients who have been diagnosed with metastatic breast cancer that has progressed
      since their previous cancer treatment and that cannot be removed completely by surgery are
      eligible to be treated within this trial.Treatment with a new drug called Progesterone
      Receptor Antagonist ZK 230211 (ZK PRA) targets the progesterone receptor which may be
      expressed on breast cancer tumour cells. Therefore only patients with this progesterone
      receptor on their tumour cells can be included in this study.Progesterone receptor
      antagonists (including onapristone) have already shown efficacy in postmenopausal women with
      advanced breast cancer (Klijn et al. 2000). This phase II study investigates the efficacy
      (proof of concept), safety and tolerability of ZK PRA at two dose levels (25 mg and 100 mg)
      before initiating pivotal phase III trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o.</measure>
    <time_frame>month 3, month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability</measure>
    <time_frame>ongoing thoughout the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of ZK PRA</measure>
    <time_frame>baseline, month1,2,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of ZK PRA on quality of life (QoL)</measure>
    <time_frame>baseline, month 1,2,3,4,5,6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform exploratory analysis of biomarkers</measure>
    <time_frame>baseline, month 1, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) / Duration of response - in the subset of patients with measurable disease</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonaprisan (ZK 230211, BAY86-5044)</intervention_name>
    <description>25 mg daily oral treatment</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonaprisan (ZK 230211, BAY86-5044)</intervention_name>
    <description>100 mg daily oral treatment</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women defined as: aged &gt;/= 50 years with amenorrhea for at least 12
             months or aged &lt; 50 years with 6 months of spontaneous amenorrhea and follicle
             stimulating hormone (FSH) level within postmenopausal range (&gt; 40 mIU/ml) or having
             undergone bilateral oophorectomy

          -  Histologically or cytologically confirmed breast cancer

          -  Metastatic breast cancer (Stage IV according to UICC - Union Internationale Contre
             Cancer - criteria, Version 6)

          -  Progesterone receptor-positive tumors

          -  Patients must be considered candidates for endocrine therapy (no other therapies for
             breast cancer are required)

          -  Disease progression after first-line endocrine therapy for advanced breast cancer
             (i.e. with tumor remission or stabilization lasting at least 3 months under endocrine
             therapy)

          -  At least one measurable or non-measurable tumor lesion (according to RECIST criteria)

          -  WHO Performance status 1

          -  Adequate function of major organs and systems:

               -  Hematopoietic:

                    -  Hemoglobin: 10 g/dL

                    -  Absolute neutrophil count: 1,500/mm3

                    -  Platelet count: 100,000/mm3

               -  Hepatic:

                    -  Total bilirubin: 1.5 times the upper limit of normal

                    -  AST/ALT: 2.5 times the upper limit of normal

               -  Renal: Creatinine: 1.5 times the upper limit of normal

               -  Gynecological: Endometrial thickness (in non-hysterectomized women) &lt;/= 10 mm
                  double layer

               -  No other uncontrolled concurrent illness

          -  Adequate recovery from previous surgery, radiation and chemotherapy

          -  Written informed consent

        Exclusion Criteria:

          -  Presence of any of the following conditions:

               -  life-threatening metastatic visceral disease (extensive hepatic involvement)

               -  any metastases to the central nervous system (CNS)

               -  pulmonary lymphangitic metastases involving more than 50% of the lung

          -  More than one prior endocrine treatment for advanced breast cancer

          -  Previous combination of endocrine treatment with any other type of treatment (except
             chemotherapy), or previous sequential endocrine treatments (if there was disease
             progression between treatments) are not permitted in this trial.

          -  Patients with breast cancer HER-2 positive or with unknown HER-2 status are not
             eligible.

          -  Malignancies or history of prior malignancy other than carcinoma in situ of the cervix
             or uterus, or basal and squamous cell carcinoma of the skin

          -  Intake of CYP3A4 inhibitors less than 2 weeks before start of study treatment

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 milliseconds (ms)

          -  A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family
             history of Long QT Syndrome)

          -  The use of concomitant medications that prolong the QT/QTc interval

          -  Other investigational drug therapies less than 4 weeks or at least 5 half-lives before
             start of study treatment (less than 4 weeks for faslodex and less than 2 weeks for any
             other endocrine therapy)

          -  Expectation that the patient will not be able to complete at least 3 months of therapy

          -  Unwillingness or inability to comply with the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <zip>10-226</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Växjö</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <reference>
    <citation>Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8. doi: 10.1093/annonc/mdt216. Epub 2013 Jun 20.</citation>
    <PMID>23788750</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer stage IV</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>mBC</keyword>
  <keyword>Stage IV breast cancer</keyword>
  <keyword>Hormone receptor positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

